Leaderboards/Soft tissue tumor case studies

Soft tissue tumor case studies

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Tatiana Georgiesh
Oslo University Hospital
2
Kyle M. Devins
Harvard University
3
Roelof van Ewijk
Princess Máxima Center
4
Jean-Philippe Brosseau
Centre Hospitalier Universitaire de Sherbrooke
5
Raul Perret
Université de Bordeaux
6
Matthias Bieg
German Cancer Research Center
7
Mindy X. Wang
The University of Texas MD Anderson Cancer Center
8
Annie K. Joseph
Mayo Clinic
9
Xiaojing Lu
Shanghai Jiao Tong University
10
Ryuji Iwamura
University of Occupational and Environmental Health Japan

Rising Stars Papers

1
Atypical Spindle Cell/Pleomorphic Lipomatous Tumor With Sarcomatous Transformation: Clinicopathologic and Molecular Analysis of 4 Cases
Modern Pathology|2024
11 cit.
2
Uterine Inflammatory Myofibroblastic Tumors
The American Journal of Surgical Pathology|2024
8 cit.
3
Adult Granulosa Cell Tumors of the Ovary With Tubular Differentiation
The American Journal of Surgical Pathology|2025
7 cit.
4
Large and Extensive Multilocular Peritoneal Inclusion Cysts Lack Genomic Alterations and Follow an Indolent Clinical Course Despite Rare Recurrences
The American Journal of Surgical Pathology|2024
6 cit.
5
Deciphering Pseudoendocrine Sarcoma: A Clinicopathological, Molecular, and Epigenetic Study Suggesting Biological Links With Solid Pseudopapillary Neoplasm of the Pancreas
Modern Pathology|2025
6 cit.
6
Low-Grade Endometrial Stromal Sarcoma
The American Journal of Surgical Pathology|2025
5 cit.
7
GLI1-Altered Tumors of the Ovary: A Report of 4 Cases of an Underrecognized Neoplasm That May Mimic Sex Cord–Stromal Tumors
Modern Pathology|2025
4 cit.
8
Uterine Sarcomas With Recurrent KDM2B Gene Fusions: Three Cases of a Possible Novel Subtype of High-Grade Endometrial Stromal Sarcoma
Modern Pathology|2025
4 cit.
9
Comparison of medical history documentation efficiency and quality based on GPT-4o: a study on the comparison between residents and artificial intelligence
Frontiers in Medicine|2025
3 cit.
10
Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma
JCO Precision Oncology|2025
3 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Yun-Shao Sung
Memorial Sloan Kettering Cancer Center
2
Lipika Goyal
Stanford Medicine
3
Giby V. George
Natera (United States)
4
Erin R. Rudzinski
Indiana University School of Medicine
5
Amy Sheen
Royal North Shore Hospital
6
Jean-Baptiste Courrèges
Institut Bergonié
7
Eberhad Stoeckle
Institut Bergonié
8
Josefina Cruz
Hospital Universitario de Canarias
9
Gregory W. Charville
Palo Alto University
10
Julie Paik
Touro University Nevada

Emerging Leaders Papers

1
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
New England Journal of Medicine|2023
541 cit.
2
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Nature Medicine|2024
66 cit.
3
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> fusions/rearrangements.
Journal of Clinical Oncology|2022
54 cit.
4
Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.
Journal of Clinical Oncology|2023
37 cit.
5
GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics
The American Journal of Surgical Pathology|2022
27 cit.
6
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
JNCI Journal of the National Cancer Institute|2023
27 cit.
7
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Clinical Cancer Research|2024
18 cit.
8
FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures
Clinical Cancer Research|2022
15 cit.
9
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling
Annals of Oncology|2024
15 cit.
10
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
JCO Precision Oncology|2023
14 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Christopher D.�M. Fletcher
Brigham and Women's Hospital
2
Sharon W. Weiss
Tel Aviv University
3
Cristina R. Antonescu
Memorial Sloan Kettering Cancer Center
4
Jason L. Hornick
Harvard University
5
Francis S. Collins
National Human Genome Research Institute
6
Murray F. Brennan
Memorial Sloan Kettering Cancer Center
7
Markku Miettinen
National Institutes of Health
8
Alessandro Gronchi
Fondazione IRCCS Istituto Nazionale dei Tumori
9
Jean‐Michel Coindre
Université de Bordeaux
10
Wei‐Lien Wang
The University of Texas MD Anderson Cancer Center

Current Senior Leaders Papers

1
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project
Nature|2007
5.3k cit.
2
Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping
Science|1989
3.2k cit.
3
World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone
Lund University Publications (Lund University)|2002
2.8k cit.
4
Two Hundred Gastrointestinal Stromal Tumors
Annals of Surgery|2000
2.5k cit.
5
Genome sequence of the Brown Norway rat yields insights into mammalian evolution
Nature|2004
2.2k cit.
6
Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome
Nature|2003
2.2k cit.
7
The Path to Personalized Medicine
New England Journal of Medicine|2010
1.9k cit.
8
Policy: NIH to balance sex in cell and animal studies
Nature|2014
1.8k cit.
9
A vision for the future of genomics research
Nature|2003
1.7k cit.
10
Malignant fibrous histiocytoma.An Analysis of 200 Cases
Cancer|1978
1.5k cit.

Reagents for Soft tissue tumor case studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 60

Phospho-GRB10 (Ser476) (D4E6) Rabbit Monoclonal Antibody

#11817$176,415
View Evidence →
Cell Signaling TechnologyEvidence 65

PDGF Receptor beta (C82A3) Rabbit Monoclonal Antibody

#4564$157,348
View Evidence →
Agilent/DakoEvidence 63

Anti-Desmin

#M0760
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

CD 117 (c-Kit, SCF-Receptor)

Cited in 6 papers
#A4502
View Evidence →
Cell Signaling TechnologyEvidence 66

Histone H3 (3H1) Rabbit Monoclonal Antibody (HRP Conjugate)

#5192$465
View Evidence →
Cell Signaling TechnologyEvidence 61

Phospho-PEA-15 (Ser104) Antibody

#2776$366,863
View Evidence →